Publication at Second Faculty of Medicine |
2016
Abstract
Empagliflozin lowered glycated hemoglobin, weight, and blood pressure in the study EMPA REG OUTCOME. At the same time, empagliflozin decreased mortality and the incidence of heart failure.
The risk of stroke in patients treated with empagliflozin did not drop despite blood pressure decrease. Results of the study EMPA REG Outcome offer to test the hypothesis that patients with long standing type 2 diabetes treated with insulin are at risk of heart failure during diabetes therapy intensification.
Preventive measures may include an intensive treatment with diuretics. It is also necessary to verify the safety of empagliflozin in terms of the risk of stroke.